Monday, October 10, 2016
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (NASDAQ:GOOGL), Novo Nordisk (CO:NOVOb) (NVO) and Enterprise Products Partners (EPD).
Google parent Alphabet shares lagged the broader market and the Tech sector this year, but the company remains well positioned for outperformance in the long run given its focus on innovation, strategic acquisitions, the Android OS and a number of other diversification moves. In its Oct 4 event, the tech giant unveiled a range of new products including two smartphones, a 5.0 inch Pixel and a 5.5 inch Pixel XL, and an Android virtual reality headset, Daydream. However, growing competition and legal hassles remained as major headwinds. (You can read the full research report on Alphabet here>>)
Novo Nordisk shares have been laggards this year, as the Danish pharmaceutical giant has been grappling with a number of a company-specific issues on top of the unfavorable political/regulatory backdrop for the space as a whole. The company's strong presence in the Diabetes Care market and focus on therapeutic proteins within insulin is a big positive. To that end, Victoza remains a key growth area for the company. But a slew of patent expirations, growing pricing pressures for a number of its drugs and the recent decision to discontinue the development of liraglutide as a joint therapy to insulin in type I diabetes remain headwinds. The Zacks analyst discusses the pros & cons of investing in Novo Nordisk shares at this stage. (You can read the full research report on Novo Nordisk here>>)
Enterprise Products Partners shares have performed in line with the broader market this year, but lagged the energy space as a whole on NGL pricing issues and the recent uptrend in long-term interest rates. These issues notwithstanding, the Zacks analyst likes the partnership's large scale and diverse midstream asset base and multi-billion dollar projects under construction, which are likely to support meaningful distribution growth. (You can read the full research report on Enterprise Products Partners here>>)
Other noteworthy reports we are featuring today include Twitter (TWTR), Textron (NYSE:TXT) and Xerox (NYSE:XRX).
Free Access: All Zacks Research Reports
Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks. Valued at $25 each, they are yours to consult over the next 30 days absolutely free. They feature sensitive Zacks Rank information on each stock that you won't find anywhere else. See the reports free >>
You can find all of today's stock research reports here>>
Sheraz Mian
Director of Research
Note: If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Featured Reports
Bank of the Ozarks (OZRK) Hikes Dividend, Costs a Concern
The Zacks Analyst thinks that persistent hike in dividend by Bank of the Ozarks will boost investors' confidence in the stock. However, mounting non-interest expenses remain a matter of concern.
Twitter's (TWTR) Buyout Rumors Losing Steam on Scarce Bids
The covering analyst observes that Twitter's vast data is appealing for buyers, but the plethora of issues like sluggish user growth complicated by hefty price tag are proving big impediments.
Cousins (CUZ) Closes Merger with Parkway Properties
According to the Zacks analyst, the merger with Parkway Properties and Houston asset spin-off will help Cousins bolster its presence in key regions and exit troubled market.
Xerox (XRX) Remains Poised for Healthy Long-Term Growth
Xerox's three-year strategic transformation program aims incremental savings of $600 million across all segments and intends to realize cumulative cost reduction of $2.4 billion to spur growth.
Textron's (TXT) Growth Strategy Impresses
The Zacks Analyst believes that Textron's systematic inorganic growth strategy, new product offerings will drive profitability.
Exposure to Low Interest Rates a Drag on W.R. Berkley (WRB)
The covering analyst believes that W.R. Berkley's exposure to an intensely competitive insurance market with low interest rate scenario is a concern.
LabCorp (LH) Poised On Sequenom Acquisition, Forex Woes Hurt
Despite the strengthening dollar, the Zacks analyst believes Labcorp is gaining prominence in the market with the recent acquisition of Sequenom.
New Upgrades
SVB Financial (SIVB) Remains Well Positioned for Growth
According to the Zacks Analyst, SVB Financial is poised to capitalize on future opportunities based on its sturdy capital position. Also, rising non-interest income will aid top-line growth.
Analog Devices (ADI) Rides High on Strong Market Position
The covering analyst believes that Analog Devices is well positioned in markets such as industrial, auto and communication, which have impressive growth prospects.
Big 5's (BGFV) Strategic Efforts to Keep it on Growth Path
The Zacks analyst thinks that Big 5's merchandising plans, eCommerce growth and solid store network will help it capture market share and fuel growth. It's third quarter view also remain upbeat.
New Downgrades
Stericycle (NASDAQ:SRCL) Plagued by Macroeconomic Challenges, Margin Woes
Stericycle has lowered its earnings guidance for 2016 due to macroeconomic challenges and unfavorable foreign exchange rates as margin woes related to high operating costs linger.
Low Interest Rate, Stiff Competition Dragging Intercontinental (ICE)
The Zacks analyst believes stiff competition, low interest rate, challenging regulations and volatile industry trends raise concern over Intercontinental Exchange's operational results.
Competitive Market and Slower Omnigraft Ramp Hurt Integra (IART)
According to the covering analyst, a highly competitive market for hospital/physician office instrumentation and slower ramp of Omnigraft are going to affect Integra Lifesciences' performance.
XEROX CORP (XRX): Free Stock Analysis Report
TEXTRON INC (TXT): Free Stock Analysis Report
TWITTER INC (TWTR): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ALPHABET INC-A (GOOGL): Free Stock Analysis Report
ENTERPRISE PROD (EPD): Free Stock Analysis Report
Original post
Zacks Investment Research